KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash from Operations (2016 - 2026)

Gilead Sciences filings provide 17 years of Cash from Operations readings, the most recent being 3327000000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 11.83% to 3327000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 10019000000.0, a 7.47% decrease, with the full-year FY2025 number at 10019000000.0, down 7.47% from a year prior.
  • Cash from Operations hit 3327000000.0 in Q4 2025 for Gilead Sciences, down from 4108000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4309000000.0 in Q3 2024 to a low of 827000000.0 in Q2 2025.
  • Median Cash from Operations over the past 5 years was 2327000000.0 (2021), compared with a mean of 2465450000.0.
  • The widest YoY moves for Cash from Operations: up 145.53% in 2024, down 43.33% in 2024.
  • Gilead Sciences' Cash from Operations stood at 3205000000.0 in 2021, then decreased by 19.91% to 2567000000.0 in 2022, then fell by 15.5% to 2169000000.0 in 2023, then skyrocketed by 37.16% to 2975000000.0 in 2024, then grew by 11.83% to 3327000000.0 in 2025.
  • The last three reported values for Cash from Operations were 3327000000.0 (Q4 2025), 4108000000.0 (Q3 2025), and 827000000.0 (Q2 2025) per Business Quant data.